Detail of "64744-50-9"

Supplier Location
Supplier Location
- China (Mainland)(15)
- India(3)
- Singapore(1)
- Germany(1)
- Hong Kong(1)
Business Type
Business Type
- Lab/Research institutions(2)
- Manufacturers(0)
- Trading Company(18)
Certificates
Certificates
- ISO(1)
- Production License (0)

Display：

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Preparation of gabapentin with high purity: All Rights Reserved. Preparation of gabapentin with high purity.Several substances are used for example 64744-50-9 and 64-17-5 which are their cas registry numbers. Wu, Fanhong; Shu, Haiying; Zhang, Wei; Yao, Lingang; Lu, Qingchang; Deng, Decai (Shanghai Ecust Biomedicine Co., Ltd., Peop. Rep. China). Faming Zhuanli Shenqing Gongkai Shuomingshu CN 1891684 A 10 Jan 2007, 7pp. (Chinese). (People's Republic of China). CODEN: CNXXEV. APPLICATION: CN 2010-27467 4 Jul 2005. DOCUMENT TYPE: Patent CA Section: 34 (Amino Acids, Peptides, and Proteins) The method comprises (A) heating and refluxing gabapentin lactam in the presence of hydrochloric acid, directly cooling for gabapentin hydrochloride, filtering; (B) mixing gabapentin hydrochloride and water at wt. rate of 1:1.5-1:2.5, heating and dissolving, regulating pH with alkali to basic for crude product gabapentin; (C) refining crude product gabapentin via alc. aq. soln. for title pure gabapentin. The alc. comprises methanol, Et alc., Pr alc. or Bu alc., or their mixt. .

Process for producing injectable gabapentin compositions: Process for producing injectable gabapentin compositions. Hildebrand, Keith R.; Page, Linda M.; Lane, Deanna S.; Elsberry, Dennis D.; Clarahan, David A.; Ratnayake, Jayantha H. (Medtronic, Inc., USA). U.S. Pat. Appl. Publ. US 2005004220 A1 6 Jan 2005, 9 pp., Cont.-in-part of U.S.Several reagents with their cas registry numbers 64744-50-9 and 1310-73-2 are used here. Ser. No. 611,459. (English). (United States of America). CODEN: USXXCO. CLASS: ICM: A61K031-195. NCL: 514561000. APPLICATION: US 2004-808113 24 Mar 2004. PRIORITY: US 2003-611459 1 Jul 2003; US 2003-PV513681 23 Oct 2003; US 2003-PV513682 23 Oct 2003. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Injectable compns. contg. gabapentin and processes for prepg. sterile injectable compns. contg. gabapentin are discussed. The process includes subjecting the compns. to heat. Heating results in increased prodn. of gabapentin lactam, which has previously been shown to be toxic. Surprisingly, heated injectable compns. contg. gabapentin are found to be non-toxic when administered intrathecally. Thus, heating for the purposes of sterilization or to assure sterility provides a viable option in the prodn. of injectable compns. contg. gabapentin. .